PMID- 37869236
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1920-454X (Electronic)
IS  - 1920-4531 (Print)
IS  - 1920-4531 (Linking)
VI  - 14
IP  - 5
DP  - 2023 Oct
TI  - The Impact of Omitting 5-FU Bolus From mFOLFOX6 Chemotherapy Regimen on 
      Hematological Adverse Events Among Patients With Metastatic Colorectal Cancer.
PG  - 392-400
LID - 10.14740/wjon1690 [doi]
AB  - BACKGROUND: Metastatic colorectal cancer (mCRC) is often treated with a mFOLFOX6 
      regimen. The 5-fluorouracil (5-FU) bolus is often omitted from the regimen to 
      reduce the risk of hematological adverse events (AEs) in patients with poor 
      performance status. We aimed to investigate the incidence of hematological AEs in 
      Asian patients with mCRC who were treated with the mFOLFOX6 with and without 5-FU 
      bolus dosing. METHODS: This retrospective chart review was conducted at King 
      Chulalongkorn Memorial Hospital, Thailand from June 2021 to June 2022. The 
      primary endpoints were hematological AEs. Secondary endpoints were any AEs. The 
      comparison of continuous data was conducted with an independent t-test. The 
      Chi-squared test was used to compare categorical data. RESULTS: From 110 
      patients, we found that hematological and non-hematological AEs of any grade in 
      the two groups were not significantly different. However, patients in the bolus 
      arm had a significantly lower absolute neutrophil count (ANC) than those in the 
      non-bolus arm (mean difference = 43.13 (95% confidence interval (CI): 20.74, 
      65.51), P-value = 0.0002). A subgroup analysis in patients who received 
      first-line treatment with mFOLFOX6 showed that the bolus arm had a significantly 
      lower ANC (mean difference = 46.01 (95% CI: 19.99, 72.03), P-value = 0.0007). 
      CONCLUSIONS: mCRC patients who were treated with bolus 5-FU had lower ANC. The 
      5-FU bolus omission from the mFOLFOX6 regimen may be required in patients with a 
      high risk of neutropenia.
CI  - Copyright 2023, Areepium et al.
FAU - Areepium, Nutthada
AU  - Areepium N
AUID- ORCID: 0000-0002-9917-833X
AD  - Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, 
      Chulalongkorn University, Bangkok, Thailand.
FAU - Sapapsap, Bannawich
AU  - Sapapsap B
AUID- ORCID: 0000-0002-9119-5610
AD  - Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha 
      University, Chonburi, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20230920
PL  - Canada
TA  - World J Oncol
JT  - World journal of oncology
JID - 101564097
PMC - PMC10588498
OTO - NOTNLM
OT  - 5-fluorouracil
OT  - Adverse event
OT  - Metastatic colorectal cancer
OT  - mFOLFOX6
COIS- There is nothing to declare.
EDAT- 2023/10/23 06:48
MHDA- 2023/10/23 06:49
PMCR- 2023/09/20
CRDT- 2023/10/23 04:51
PHST- 2023/07/27 00:00 [received]
PHST- 2023/08/30 00:00 [accepted]
PHST- 2023/10/23 06:49 [medline]
PHST- 2023/10/23 06:48 [pubmed]
PHST- 2023/10/23 04:51 [entrez]
PHST- 2023/09/20 00:00 [pmc-release]
AID - 10.14740/wjon1690 [doi]
PST - ppublish
SO  - World J Oncol. 2023 Oct;14(5):392-400. doi: 10.14740/wjon1690. Epub 2023 Sep 20.